Literature DB >> 11687586

RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase.

Tudor Badea1, Florin Niculescu, Lucian Soane, Matthew Fosbrink, Hila Sorana, Violeta Rus, Moon L Shin, Horea Rus.   

Abstract

Proliferation of aortic smooth muscle cells contributes to atherogenesis and neointima formation. Sublytic activation of complement, particularly C5b-9, induces cell cycle progression in aortic smooth muscle cells. RGC-32 is a novel protein that may promote cell cycle progression in response to complement activation. We cloned human RGC-32 cDNA from a human fetal brain cDNA library. The human RGC-32 cDNA encodes a 117-amino acid protein with 92% similarity to the rat and mouse protein. Human RGC-32 maps to chromosome 13 and is expressed in most tissues. Sublytic complement activation enhanced RGC-32 mRNA expression in human aortic smooth muscle cells and induced nuclear translocation of the protein. RGC-32 was physically associated with cyclin-dependent kinase p34CDC2 and increased the kinase activity in vivo and in vitro. In addition, RGC-32 was phosphorylated by p34CDC2-cyclin B1 in vitro. Mutation of RGC-32 protein at Thr-91 prevented the p34CDC2-mediated phosphorylation and resulted in loss of p34CDC2 kinase enhancing activity. Overexpression of RGC-32 induced quiescent aortic smooth muscle cells to enter S-phase. These data indicate that cell cycle activation by C5b-9 may involve p34CDC2 activity through RGC-32. RGC-32 appears to be a cell cycle regulatory factor that mediates cell proliferation, both as an activator and substrate of p34CDC2.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687586     DOI: 10.1074/jbc.M109354200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

1.  Response gene to complement 32 promotes vascular lesion formation through stimulation of smooth muscle cell proliferation and migration.

Authors:  Jia-Ning Wang; Ning Shi; Wei-Bing Xie; Xia Guo; Shi-You Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-06-02       Impact factor: 8.311

Review 2.  The role of complement system in adipose tissue-related inflammation.

Authors:  Sonia I Vlaicu; Alexandru Tatomir; Dallas Boodhoo; Stefan Vesa; Petru A Mircea; Horea Rus
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

Review 3.  The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription.

Authors:  Matthew Fosbrink; Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

4.  Identification of genes deregulated during serum-free medium adaptation of a Burkitt's lymphoma cell line.

Authors:  L Zander; M Bemark
Journal:  Cell Prolif       Date:  2008-02       Impact factor: 6.831

Review 5.  The role of complement activation in atherosclerosis.

Authors:  Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 6.  Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Jacob Danoff; Hassan Madani; Adam Sugarman; Florin Niculescu; Petru A Mircea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

7.  Responses of cultured human keratocytes and myofibroblasts to ethyl pyruvate: a microarray analysis of gene expression.

Authors:  Stephen A K Harvey; Emily Guerriero; Nahthai Charukamnoetkanok; Jordan Piluek; Joel S Schuman; Nirmala Sundarraj
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-06       Impact factor: 4.799

8.  Overexpression of response gene to complement 32 (RGC32) promotes cell invasion and induces epithelial-mesenchymal transition in lung cancer cells via the NF-κB signaling pathway.

Authors:  Qinying Sun; Xiaopeng Yao; Yunye Ning; Wei Zhang; Guowu Zhou; Yuchao Dong
Journal:  Tumour Biol       Date:  2013-05-29

9.  Epigenetic modifications induced by RGC-32 in colon cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Matthew Fosbrink; Vingh Nguyen; Philippe Azimzadeh; Violeta Rus; Hegang Chen; Petru A Mircea; Abulkalam Shamsuddin; Horea Rus
Journal:  Exp Mol Pathol       Date:  2009-10-31       Impact factor: 3.362

Review 10.  The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.

Authors:  Alexandru Tatomir; Anamaria Talpos-Caia; Freidrich Anselmo; Adam M Kruszewski; Dallas Boodhoo; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.